OliverLenzMDMBA FACP FASN

PubMed

• 43 citations
  Phosphate control in end-stage renal disease: barriers and opportunities
  Ahmed A. Waheed, Fernando Pedraza, Oliver Lenz, Tamara Isakova
  Nephrology, Dialysis, Transplantation. 2013-12-01
• 141 citations
  Outcomes in African Americans and Hispanics with lupus nephritis
  Gabriel Contreras, Oliver Lenz, V. Pardo, E. Borja, C. Cely
  Kidney International. 2006-05-02
• 136 citations
  Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.
  Luis M. Ortega, Duane R. Schultz, Oliver Lenz, Pardo, Gabriel Contreras
  Lupus. 2010-04-01

Journal Articles

• Comparison of Mortality of ESRD Patients with Lupus by Initial Dialysis Modality  
  Contreras G, Pagan J, Chokshi R, Virmani S, Diego JM, Byers P, Isakova T, Munoz Mendoza J, Nayer A, Contreras JR, Panama G, Lenz O, Carpintero M, Muchayi T, Roth D, Clin J Am Soc Nephrol. Clin J Am Soc Nephrol, 1/1/2014
• Phosphate Control in End Stage Renal Disease: Barriers and Opportunities  
  Waheed AA, Pedraza F, Lenz O, Isakova T, Nephrol Dial Transplant, 1/1/2013
• Moving Points: Maintenance Therapy of Lupus Nephritis: Do we now have a plan?  
  Lenz O, Waheed A, Baig A, Pop A, Contreras G, Clin J Am Soc Nephrol, 1/1/2013
• Acute Renal Infarction: An Underdiagnosed Disorder  
  Baig A, Ciril E, Contreras G, Lenz O, Borra S, J Med Cases, 1/1/2012
• An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review  
  Vodopivec D, Rubio JE, Fornoni A, Lenz O, Case Report Med, 1/1/2012
• Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn?  
  Ortega LM, Contreras G, Lenz O, Nefrologia, 1/1/2009
• : Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenstrom's Macroglobulinemia: a case report  
  Castro H, Valenzuela R, Ruiz P, Lenz O, Monrroy M, Cases J, 1/1/2008
• Combination therapy with renin-angiotensin blockers: will amlodipine replace hydrochlorothiazide?  
  Tejada T, Fornoni A, Lenz O, Materson BJ, Current Cardiol Rep, 1/1/2007
• Maximizing Permanent Vascular Access Use in Hemodialysis Patients  
  Madhanasekaran V, Lenz O, Roth D, Touch Briefings, End-Stage Renal Disease – Vascular Access, 1/1/2007
• Percutaneous management of perianastomotic stenosis in arteriovenous fistulae Results of a prospective study  
  Asif A, Lenz O, Merrill D, Cherla G, Cipleu C, Ellis R, Francois B, Epstein DL, Pennell P, Kidney Int, 1/1/2006
• Low IGFBP-2 expression is responsible for increased IRS-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis  
  Fornoni A, Rosenzweig SA, Lenz O, Rivera A, Striker GE, Elliot SJ, Endocrinology, 1/1/2006
• hronic kidney disease care delivered by US family medicine and internal medicine trainees: Results from an online survey  
  Fornoni A, Lenz O, BMC Medicine, 1/1/2006
• The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure  
  DeFreitas O, Lenz O, Fornoni A, Materson B, Vascular Health and Risk Management, 1/1/2006
• Creation of secondary arteriovenous fistulas: maximizing fistulas in prevalent hemodialysis patients  
  Asif A, Unger SW, Briones P, Merrill D, Cherla G, Lenz O, Roth D, Pennell P, Semin Dial, 1/1/2005
• Treatment options for severe lupus nephritis  
  Lenz O, Contreras G, Arch Immunol Ther Exp, 1/1/2004
• End-organ susceptibility as a determinant of renal disease in hypertension  
  Raij L, Madias NE, Lenz O, Epstein M, Jaimes EA, Materson BJ, Banerjee D, Preston RA, Roth D, Abraira C, Kidney Int, 1/1/2003
• Join now to see all